• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估针对雇主人群的结直肠癌筛查多靶点粪便 DNA 检测的外展方法。

Evaluating Outreach Methods for Multi-Target Stool DNA Test for Colorectal Cancer Screening Among an Employer Population.

机构信息

Vanderbilt University Medical Center, Nashville, TN, USA.

Metro Nashville Public Schools, Nashville, TN, USA.

出版信息

J Prim Care Community Health. 2021 Jan-Dec;12:21501327211037892. doi: 10.1177/21501327211037892.

DOI:10.1177/21501327211037892
PMID:34382887
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8366118/
Abstract

INTRODUCTION/OBJECTIVES: Despite compelling evidence of clinical and economic benefits, adherence to colorectal cancer (CRC) screening remains low. Increasing public awareness through various outreach methods may improve screening uptake. The objective of this study was to evaluate the uptake of non-invasive multi-target stool DNA (mt-sDNA) by different outreach methods in an average-risk employer population.

METHODS

This retrospective observational study included CRC screening-eligible individuals aged ≥50 years insured by the Metropolitan Nashville Public Schools (MNPS) employee healthcare plan. The study intervention arms included population-based outreach and office visit-based interaction. The mt-sDNA completion rate (proportion of individuals who return the mt-sDNA kit after consenting to have it shipped to their home), proportion of patients who performed follow-up colonoscopy after a positive test, and time to follow-up colonoscopy were assessed.

RESULTS

A total of 167 mt-sDNA kits were shipped to eligible participants (aged 50-64 years) in the population-based outreach arm. In the office visit-based interaction arm, a total of 132 mt-sDNA kits were shipped to eligible participants (aged ≥50 years). The mt-sDNA completion rate was significantly higher for office visit-based interaction as compared to population-based outreach (76.8% vs 53.5%;  < .001) among those aged 50 to 64 years. While all patients aged 50 to 64 years with a positive mt-sDNA result received a follow-up colonoscopy in both arms, the median time to follow-up colonoscopy was shorter among the population-based outreach (55 vs 136 days;  < .05).

CONCLUSIONS

Office visit-based interaction was associated with a higher mt-sDNA completion rate as compared to the population-based outreach among average-risk, CRC screening-eligible individuals aged 50 to 64 years old.

摘要

简介/目的:尽管有令人信服的临床和经济效益证据,但结直肠癌(CRC)筛查的依从性仍然很低。通过各种外展方法提高公众意识可能会提高筛查率。本研究的目的是评估通过不同外展方法在平均风险雇主人群中对非侵入性多靶点粪便 DNA(mt-sDNA)的接受程度。

方法

本回顾性观察性研究包括年龄在 50 岁及以上且有资格接受 CRC 筛查的大都会纳什维尔公立学校(MNPS)员工医保计划的参保者。研究干预组包括基于人群的外展和基于就诊的互动。评估 mt-sDNA 完成率(在同意将 mt-sDNA 试剂盒寄送到其家中后返回试剂盒的个体比例)、阳性检测后进行后续结肠镜检查的患者比例以及后续结肠镜检查的时间。

结果

在基于人群的外展组中,共向符合条件的参与者(年龄在 50-64 岁之间)寄出了 167 个 mt-sDNA 试剂盒。在基于就诊的互动组中,共向符合条件的参与者(年龄≥50 岁)寄出了 132 个 mt-sDNA 试剂盒。在年龄在 50-64 岁之间的人群中,与基于人群的外展相比,基于就诊的互动的 mt-sDNA 完成率明显更高(76.8%对 53.5%;<0.001)。虽然在两条臂中,所有年龄在 50-64 岁之间 mt-sDNA 阳性结果的患者均接受了后续结肠镜检查,但基于人群的外展组的中位随访结肠镜检查时间更短(55 对 136 天;<0.05)。

结论

与基于人群的外展相比,基于就诊的互动在年龄在 50-64 岁的平均风险、CRC 筛查合格人群中与更高的 mt-sDNA 完成率相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47a6/8366118/81f5163f1149/10.1177_21501327211037892-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47a6/8366118/81f5163f1149/10.1177_21501327211037892-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47a6/8366118/81f5163f1149/10.1177_21501327211037892-fig1.jpg

相似文献

1
Evaluating Outreach Methods for Multi-Target Stool DNA Test for Colorectal Cancer Screening Among an Employer Population.评估针对雇主人群的结直肠癌筛查多靶点粪便 DNA 检测的外展方法。
J Prim Care Community Health. 2021 Jan-Dec;12:21501327211037892. doi: 10.1177/21501327211037892.
2
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.与结直肠癌筛查相关的医疗保健成本、资源利用和生产力损失。
Expert Rev Pharmacoecon Outcomes Res. 2023 Jul-Dec;23(7):843-852. doi: 10.1080/14737167.2023.2220965. Epub 2023 Jul 18.
3
Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.多靶点粪便DNA检测增加了既往不依从的医疗保险患者的结直肠癌筛查率。
World J Gastroenterol. 2017 Jan 21;23(3):464-471. doi: 10.3748/wjg.v23.i3.464.
4
Cost-Effectiveness of Outreach Strategies for Stool-Based Colorectal Cancer Screening in a Medicaid Population.基于粪便的大肠癌筛查在医疗补助人群中的外展策略的成本效益。
Popul Health Manag. 2022 Jun;25(3):343-351. doi: 10.1089/pop.2021.0185. Epub 2021 Dec 24.
5
Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.基于粪便的结直肠癌筛查和阳性检测后结肠镜检查中患者依从性对临床结局的影响。
Cancer Prev Res (Phila). 2021 Sep;14(9):845-850. doi: 10.1158/1940-6207.CAPR-21-0075. Epub 2021 May 21.
6
Alaska Native Patient and Provider Perspectives on the Multitarget Stool DNA Test Compared With Colonoscopy for Colorectal Cancer Screening.阿拉斯加原住民患者和医疗服务提供者对多靶点粪便DNA检测与结肠镜检查用于结直肠癌筛查的看法。
J Prim Care Community Health. 2019 Jan-Dec;10:2150132719884295. doi: 10.1177/2150132719884295.
7
Evaluation of a multimedia outreach campaign for a multi-target stool DNA test for colorectal cancer screening among non-medicare employer population in the United States.针对美国非医疗保险雇主人群开展的一项用于结直肠癌筛查的多靶点粪便DNA检测的多媒体宣传活动评估。
Prev Med Rep. 2022 May 31;28:101848. doi: 10.1016/j.pmedr.2022.101848. eCollection 2022 Aug.
8
Barriers to Follow-Up Colonoscopy After Positive FIT or Multitarget Stool DNA Testing.阳性粪便免疫化学检测或多靶点粪便 DNA 检测后的结肠镜随访障碍。
J Am Board Fam Med. 2021 Jan-Feb;34(1):61-69. doi: 10.3122/jabfm.2021.01.200345.
9
Colorectal Neoplasia Detection in Individuals With Positive Multitarget Stool DNA Tests: Data From the New Hampshire Colonoscopy Registry.多靶点粪便 DNA 检测阳性个体的结直肠肿瘤检测:来自新罕布什尔州结肠镜检查登记处的数据。
J Clin Gastroenterol. 2022;56(5):419-425. doi: 10.1097/MCG.0000000000001554.
10
Early Adoption of a Multitarget Stool DNA Test for Colorectal Cancer Screening.早期采用多靶点粪便DNA检测进行结直肠癌筛查。
Mayo Clin Proc. 2017 May;92(5):726-733. doi: 10.1016/j.mayocp.2017.01.019.

引用本文的文献

1
Effectiveness of workplace cancer screening interventions: a systematic review.工作场所癌症筛查干预措施的效果:系统评价。
BMC Cancer. 2024 Aug 12;24(1):999. doi: 10.1186/s12885-024-12649-0.
2
Barriers and facilitators of colorectal cancer screening using the 5As framework: A systematic review of US studies.使用5A框架进行结直肠癌筛查的障碍与促进因素:对美国研究的系统评价
Prev Med Rep. 2023 Jul 29;35:102353. doi: 10.1016/j.pmedr.2023.102353. eCollection 2023 Oct.
3
Inappropriate Multi-Target Stool DNA Use for Colorectal Cancer Screening: Risks, Compliance, and Outcomes.

本文引用的文献

1
Effectiveness of a mailed fecal immunochemical test outreach: a Medicare Advantage pilot study.邮寄粪便免疫化学检测外展服务的有效性:一项医疗保险优势试点研究。
Therap Adv Gastroenterol. 2020 Sep 9;13:1756284820945388. doi: 10.1177/1756284820945388. eCollection 2020.
2
Impact of Health Insurance, Poverty, and Comorbidities on Colorectal Cancer Screening: Insights from the Medical Expenditure Panel Survey.医疗保险、贫困和合并症对结直肠癌筛查的影响:来自医疗支出调查的见解。
Dig Dis Sci. 2021 Jan;66(1):70-77. doi: 10.1007/s10620-020-06541-7. Epub 2020 Aug 20.
3
Barriers and facilitators towards colonoscopy: a qualitative systematic review.
不适当的多靶点粪便DNA用于结直肠癌筛查:风险、依从性和结果
Cureus. 2023 Jun 16;15(6):e40506. doi: 10.7759/cureus.40506. eCollection 2023 Jun.
4
Evaluation of a multimedia outreach campaign for a multi-target stool DNA test for colorectal cancer screening among non-medicare employer population in the United States.针对美国非医疗保险雇主人群开展的一项用于结直肠癌筛查的多靶点粪便DNA检测的多媒体宣传活动评估。
Prev Med Rep. 2022 May 31;28:101848. doi: 10.1016/j.pmedr.2022.101848. eCollection 2022 Aug.
结肠镜检查的障碍和促进因素:定性系统评价。
Eur J Cancer Prev. 2021 May 1;30(3):232-238. doi: 10.1097/CEJ.0000000000000615.
4
AGA White Paper: Roadmap for the Future of Colorectal Cancer Screening in the United States.AGA 白皮书:美国结直肠癌筛查的未来路线图。
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2667-2678.e2. doi: 10.1016/j.cgh.2020.06.053. Epub 2020 Jul 4.
5
Colorectal cancer statistics, 2020.2020 年结直肠癌统计数据。
CA Cancer J Clin. 2020 May;70(3):145-164. doi: 10.3322/caac.21601. Epub 2020 Mar 5.
6
Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening: Real-world data from a large cohort of older adults.结直肠癌筛查多靶点粪便DNA检测的横断面依从性:来自一大群老年人的真实世界数据。
J Med Screen. 2021 Mar;28(1):18-24. doi: 10.1177/0969141320903756. Epub 2020 Feb 13.
7
Lower Adherence: A Description of Colorectal Cancer Screening Barrier Talk.较低的依从性:结直肠癌筛查障碍的描述。
J Health Commun. 2020;25(1):43-53. doi: 10.1080/10810730.2019.1697909. Epub 2019 Dec 4.
8
Stool-Based Tests Vs Screening Colonoscopy for the Detection of Colorectal Cancer.基于粪便的检测与筛查结肠镜检查在结直肠癌检测中的比较
Gastroenterol Hepatol (N Y). 2019 Aug;15(8):437-440.
9
Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis.评估旨在提高美国结直肠癌筛查率的干预措施:系统评价和荟萃分析。
JAMA Intern Med. 2018 Dec 1;178(12):1645-1658. doi: 10.1001/jamainternmed.2018.4637.
10
Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.多靶点粪便DNA检测增加了既往不依从的医疗保险患者的结直肠癌筛查率。
World J Gastroenterol. 2017 Jan 21;23(3):464-471. doi: 10.3748/wjg.v23.i3.464.